Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial
Max Seidensticker1, Osman Öcal1, Kerstin Schütte2, Peter Malfertheiner3, Thomas Berg4, Christian Loewe5, Heinz Josef Klümpen6, Otto van Delden7, Muzaffer Reha Ümütlü1, Najib Ben Khaled3, Enrico Narciso de Toni3, Ricarda Seidensticker1, Ali Aghdassi8, Albert Tran9, Jean-Pierre Bronowicki10, Bora Peynircioglu11, Bruno Sangro12, Maciej Pech13, Jens Ricke1
1Department of Radiology, University Hospital, LMU Munich, Munich, Germany
2Department of Internal Medicine and Gastroenterology, Niels-Stensen-Kliniken Marienhospital, Osnabrück, Germany
3Department of Medicine II, University Hospital, LMU Munich, Munich, Germany
4Klinik und Poliklinik für Gastroenterologie, Sektion Hepatologie, Universitätsklinikum Leipzig, Germany
5Section of Cardiovascular and Interventional Radiology, Department of Bioimaging and Image-Guided Therapy, Medical University of Vienna, Vienna, Austria
6Department of Medical Oncology, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam, The Netherlands
7Department of Radiology and Nuclear Medicine, Academic University Medical Centers, University of Amsterdam, Amsterdam, the Netherlands
8Department of Medicine A, University Medicine Greifswald, 17489 Greifswald, Germany
9Pôle Appareil Digestif, Hôpital l'Archet 2, CHU Nice, Route Saint-Antoine de Ginestière - BP 3079, Nice, France
10Department of Hepatology, INSERM U1254, Hôpital de Brabois, CHU de Nancy, University of Lorraine, Nancy, France
11Department of Radiology, Hacettepe University Hospital, Ankara, Turkey
12Liver Unit, Clínica Universidad de Navarra and CIBEREHD, Pamplona, Spain
13Department of Radiology and Nuclear Medicine, University of Magdeburg, Magdeburg, Germany